{"DataElement":{"publicId":"3191478","version":"1","preferredName":"Cerebrovascular Accident Preventive Medication At Discharge Prescription Category","preferredDefinition":"Categorial class of stroke preventive prescribed medications at discharge.","longName":"STRKPR_MED_DSCHR_CAT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3191459","version":"1","preferredName":"Cerebrovascular Accident Preventive Medication At Discharge Prescription","preferredDefinition":"Prescribed stroke preventive medications at discharge","longName":"STRK_PRV_MED_DSCHRG","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3232456","version":"1","preferredName":"Cerebrovascular Accident Preventive Medication","preferredDefinition":"A sudden, nonconvulsive loss of neurologic function due to an ischemic or hemorrhagic intracranial vascular event. In general, cerebrovascular accidents are classified by anatomic location in the brain, vascular distribution, etiology, age of the affected individual, and hemorrhagic vs. nonhemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810):Used to prevent disease.:biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.","longName":"C3390:C28005:C459","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stroke","conceptCode":"C3390","definition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive","conceptCode":"C28005","definition":"Evidence of preventive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FB3C3D-9E23-07BE-E040-BB89AD437AD5","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"LUY","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3191457","version":"1","preferredName":"At Discharge Prescription","preferredDefinition":"Used to indicate position, location, or state (American Heritage Dictionary):In healthcare, discharge represents the end point of an inpatient hospital contact which consists of one or several days of care. (from Wikipedia):A doctor's order for medicine or another intervention.","longName":"C25427:C25166:C28180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"At","conceptCode":"C25427","definition":"Used to indicate position, location, or state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Patient Discharge","conceptCode":"C25166","definition":"The release of a patient from a course of care.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prescription","conceptCode":"C28180","definition":"A verbal or written order given by an authorized person instructing a patient to obtain and use a medical device, prescription or undergo a procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C038308-DD30-FB58-E040-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"ONEDATA","dateModified":"2011-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C038308-DD41-FB58-E040-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"TSESU","dateModified":"2018-05-25","changeDescription":"5/25/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3191461","version":"1","preferredName":"Cerebrovascular Accident Preventive Medication Category","preferredDefinition":"Categorial class of stroke preventive medications.","longName":"STRK_PRV_MED_CAT","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Lipid lowering agents","valueDescription":"Lipid lowering agents","ValueMeaning":{"publicId":"3191462","version":"1","preferredName":"Lipid lowering agents","longName":"3191462","preferredDefinition":"Lipid lowering agents","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C03939E-9753-2D26-E040-BB89AD4356ED","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C03939E-976C-2D26-E040-BB89AD4356ED","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Anti-diabetic agents","valueDescription":"Anti-diabetic Agent","ValueMeaning":{"publicId":"3191464","version":"1","preferredName":"Anti-diabetic Agent","longName":"3191464","preferredDefinition":"Any substance used to reduce hyperglycemia or treat disorders associated with diabetes. Based on their mechanism of action, this class of agents can be classified to the following groups: directly acting insulomimetics, which activates insulin receptors; indirectly acting insulinomimetics, which increase insulin release such as sulfonylureas or which potentiate the effect of insulin such as metformin; those act directly on the metabolism of glucose such as inhibitors of glucosidases and inhibitors of aldose reductase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-diabetic Agent","conceptCode":"C29711","definition":"Any substance used to reduce hyperglycemia or treat disorders associated with diabetes. Based on their mechanism of action, this class of agents can be classified to the following groups: directly acting insulomimetics, which activates insulin receptors; indirectly acting insulinomimetics, which increase insulin release such as sulfonylureas or which potentiate the effect of insulin such as metformin; those act directly on the metabolism of glucose such as inhibitors of glucosidases and inhibitors of aldose reductase.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C03939E-9779-2D26-E040-BB89AD4356ED","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C03939E-9792-2D26-E040-BB89AD4356ED","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Antihypertensives","valueDescription":"Antihypertensive Agent","ValueMeaning":{"publicId":"3191465","version":"1","preferredName":"Antihypertensive Agent","longName":"3191465","preferredDefinition":"Drugs used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Among the antihypertensive agents are diuretics, adrenergic beta-antagonists; andrenergic alpha-antogonists; angiotensin-converting enzyme inhibitors; calcium channel blockers; ganglionic blockers; and vasodilator agents. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antihypertensive Agent","conceptCode":"C270","definition":"Any substance used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Antihypertensive agents include diuretics, alpha-adrenergic and beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C03939E-979C-2D26-E040-BB89AD4356ED","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C03939E-97B5-2D26-E040-BB89AD4356ED","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Antiplatelets","valueDescription":"Antiplatelet Agent","ValueMeaning":{"publicId":"3191466","version":"1","preferredName":"Antiplatelet Agent","longName":"3191466","preferredDefinition":"An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiplatelet Agent","conceptCode":"C1327","definition":"An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C03939E-97BF-2D26-E040-BB89AD4356ED","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C03939E-97D8-2D26-E040-BB89AD4356ED","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Anticoagulants","valueDescription":"Anticoagulant Agent","ValueMeaning":{"publicId":"3191467","version":"1","preferredName":"Anticoagulant Agent","longName":"3191467","preferredDefinition":"Agents that prevent blood clotting. Naturally occurring agents in the blood are included only when they are used as drugs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anticoagulant Agent","conceptCode":"C263","definition":"Any agent capable of preventing blood clot formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C03939E-97E2-2D26-E040-BB89AD4356ED","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C03939E-97FB-2D26-E040-BB89AD4356ED","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3232462","version":"1","preferredName":"Cerebrovascular Accident Preventive Medicine Category","preferredDefinition":"A sudden, nonconvulsive loss of neurologic function due to an ischemic or hemorrhagic intracranial vascular event. In general, cerebrovascular accidents are classified by anatomic location in the brain, vascular distribution, etiology, age of the affected individual, and hemorrhagic vs. nonhemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810):A medical specialty primarily concerned with prevention of disease and the promotion and preservation of health in the individual.:Category; used informally to mean a class of things.","longName":"C3390:C17011:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stroke","conceptCode":"C3390","definition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive Medicine","conceptCode":"C17011","definition":"A branch of medicine that focuses on disease prevention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FB3C3D-9E79-07BE-E040-BB89AD437AD5","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"LUY","dateCreated":"2011-04-28","modifiedBy":"ONEDATA","dateModified":"2011-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C03939E-9740-2D26-E040-BB89AD4356ED","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","changeDescription":"5/29/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.\r\n","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6272292","version":"1","longName":"NINDS","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000330","version":"1","longName":"Treatment/Intervention Data","context":"NCIP"},{"publicId":"3151265","version":"1","longName":"Drugs","context":"NCIP"},{"publicId":"3188342","version":"1","longName":"Antithrombotics and Risk Factor Controlling Medications","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Which class(es) of medication","type":"Preferred Question Text","description":"Which class(es) of medications was the participant/subject prescribed at hospital discharge?","url":null,"context":"NCIP"},{"name":"NINDS CDE Project","type":"REFERENCE","description":"NINDS CDE Project","url":"http://www.commondataelements.ninds.nih.gov/","context":"NCIP"}],"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C04AB53-6AC0-A6B0-E040-BB89AD431AAA","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","changeDescription":"5/25/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}